0
Chest Infections |

An Elusive Pathogen Comes to Light: A Rare Case of Disseminated Mycobacterium szulgai in a Patient With Lung Transplant

Tushar Chopra*, MBBS; William Gibbons, MD; Anil Patel, MD; James Yossef, MD
Author and Funding Information

State University of New York at Buffalo, Department of Internal Medicine, Buffalo, NY


Chest. 2012;142(4_MeetingAbstracts):273A. doi:10.1378/chest.1366732
Text Size: A A A
Published online

Abstract

SESSION TYPE: Infectious Disease Student/Resident Case Report Posters III

PRESENTED ON: Tuesday, October 23, 2012 at 01:30 PM - 02:30 PM

INTRODUCTION: Mycobacterium szulgai, a non-tuberculous mycobacterium (NTM) is a rarely isolated scotochromogen. It is acquired through the lungs from an unknown environmental source. There are under 100 reported cases, most of whom had tuberculosis-like pulmonary disease. Infection occurs in patients with pre-existing lung disease (e.g. tuberculosis, COPD) and in immunocompromised hosts.

CASE PRESENTATION: A 55 year-old male with history of sarcoidosis, post-unilateral lung transplantation on immunosuppression since 7 years, and recurrent Pseudomonas pneumonia presented with chronic cough, generalized fatigue,and low-grade fever for 3 months. He also noticed new skin lesions on his extremities. He is a non-smoker. An initial chest CT scan revealed a chronic loculated pleural effusion with left lower lobe consolidation. Sputum gram staining detected Pseudomonas, however the sputum plus wound AFB stain was positive. Surveillance transbronchial biopsy reports,obtained from an out-of-state tertiary care center,showed no signs of rejection. However, presence of Mycobacterium szulgai was reported in the cultures in 2010 and 2009. In consultation with an infectious disease specialist and based on in-vitro sensitivities, we started treatment with isoniazid, rifampicin, ethambutol, and azithromycin. Sputum AFB culture turned negative after 4 months of treatment. The patient's skin and respiratory symptoms improved modestly. He continues to be on multi-drug macrolide-based therapy.

DISCUSSION: Mycobacterium szulgai usually causes disease and should not be considered a colonizer. Our patient had an indolent course over 2 years, eventually disseminating to the skin forming nodulo-ulcerative lesions. There are approximately 9 reported cases of cutaneous lesions and fewer cases with disseminated disease. This is the only case,to our knowledge,in a patient with lung transplant. The pathogen responds well to treatment. The patient met the American Thoracic Society criteria for NTM disease and was thus started on a multi-drug regimen based on in-vitro susceptibilities. Although clarithromycin has been successful in treating Mycobacterium szulgai, we added azithromycin for its immunomodulatory effects and fewer known interactions with rifampicin. Since infections with this organism can relapse, a triple-drug regimen based on in-vitro susceptibilities for at least 1 year after sputum cultures are negative is reasonable.

CONCLUSIONS: We hope this case encourages compliance with ATS guidelines for diagnosing NTM disease and increases awareness about Mycobacterium szulgai and its treatment.

1)Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.

2)van Ingen J, Boeree MJ, de Lange WCM, de Haas PEW, Dekhuijzen PNR, van Soolingen D. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis 2008;46:1200-5.

DISCLOSURE: The following authors have nothing to disclose: Tushar Chopra, William Gibbons, Anil Patel, James Yossef

No Product/Research Disclosure Information

State University of New York at Buffalo, Department of Internal Medicine, Buffalo, NY

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543